RESUMEN
The presence of the specific antibodies for some enterobacteria--Yersinia, Salmonella and Shigella was investigated in patients hospitalized in the period 2000-2007 with reactive arthritis and other rheumatoid diseases. The antibacterial antibodies in the diagnosis titres were found in 172 out of 1102 (15.6%) patients. Increased antibodies levels to Yersinia were detected in the sera from 113 (65.7%) of the 172 patients, for Shigella in 47 (27.3%) and for Salmonella in 12 (7.0%) cases. From all serologically positive patients 126 (73.2 %) had clinical diagnosis of reactive arthritis and 46 (26.7%) other rheumatoid diseases (ankylosing spondilytis, Reiter's syndrome, sacroilitis). The most serologically positive cases (63.9%) were of middle-age (30-50 years). There were no significant differences between sexes among serologically positive cases.
Asunto(s)
Anticuerpos Antibacterianos/sangre , Artritis Reumatoide/inmunología , Enfermedades Reumáticas/inmunología , Salmonella/inmunología , Shigella/inmunología , Yersinia/inmunología , Adolescente , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Niño , Femenino , Hospitalización , Humanos , Masculino , Persona de Mediana Edad , Factores Sexuales , Adulto JovenRESUMEN
PURPOSE: We conducted a pilot trial to assess the feasibility and tolerability of a prime/boost vaccine strategy using interferon-gamma (IFN-gamma) and autologous dendritic cells (DCs) pulsed with HLA-A2-specific prostate-specific antigen (PSA) peptides (PSA-1 [141-150]; PSA-2 [146-156]; PSA-3 [154-163]) for the treatment of 12 patients with hormone refractory prostate carcinoma. PATIENTS AND METHODS: All patients were vaccinated four times with intracutaneously injected PSA-peptide loaded DCs after subcutaneous administration of IFN-gamma 2 hr before DC administration (50 microg/m(2) body surface). Objectives were safety, clinical benefit, clinical and biochemical response, quality of life, and immunological parameters. RESULTS: The vaccination was well tolerated without any vaccination-associated adverse events. One partial and one mixed responder were identified, four patients showed stable diseases. Two patients had a decrease and four a slow-down velocity slope in the PSA serum level. All responders showed a positive DTH-response, but only two a slight increase in PSA-peptide specific T-lymphocytes. CONCLUSION: The immunotherapy with IFN-gamma and PSA-peptide loaded DCs was feasible and well tolerated. The observed responses imply a potential antitumor activity.
Asunto(s)
Vacunas contra el Cáncer/uso terapéutico , Células Dendríticas/inmunología , Inmunoterapia Adoptiva/métodos , Interferón gamma/uso terapéutico , Antígeno Prostático Específico , Neoplasias de la Próstata/terapia , Anciano , Anciano de 80 o más Años , Vacunas contra el Cáncer/efectos adversos , Vacunas contra el Cáncer/inmunología , Progresión de la Enfermedad , Antígeno HLA-A2/inmunología , Humanos , Inmunoterapia Adoptiva/efectos adversos , Inyecciones Subcutáneas , Interferón gamma/efectos adversos , Interferón gamma/inmunología , Masculino , Persona de Mediana Edad , Proyectos Piloto , Antígeno Prostático Específico/inmunología , Neoplasias de la Próstata/inmunología , Calidad de VidaRESUMEN
In a series of more than 2,500 fine needle aspirates from multiple body sites, over 200 were clinically identified as lymph nodes from patients with known or suspected malignancy. The material was obtained using the easily manipulated Aspir-Gun with a 21-gauge or 22-gauge needle and syringe. Of the 200 lymph node specimens, 100 (50%) were cytologically reported as positive for malignancy. Ninety cases had surgical pathology specimens available for comparison with the fine needle aspiration (FNA) specimens. For the 88 of these cases with satisfactory FNA specimens, evaluation of the FNA results showed a predictive value of a positive result of 96.8%. These results compare favorably with those of surgical biopsy. The malignancies present in the lymph nodes included numerous adenocarcinomas from the breast, melanoma and pulmonary small-cell carcinoma. Six cases are briefly presented in which the FNA diagnosis was more problematic. While histologic examination of tissues or organs remains the desirable benchmark of comparison, the appropriate utilization of FNA cytology to guide therapy, particularly in a patient with previously diagnosed malignancy, may obviate the need for an open biopsy. The technique is convenient for patient and physician, useful for outpatients, relatively painless and provides good correlation between cytologic morphology and histopathology.
Asunto(s)
Ganglios Linfáticos/patología , Neoplasias/diagnóstico , Adenocarcinoma/diagnóstico , Anciano , Biopsia con Aguja , Carcinoma de Células Renales/diagnóstico , Carcinoma de Células Pequeñas/diagnóstico , Femenino , Humanos , Metástasis Linfática , Masculino , Melanoma/diagnóstico , Persona de Mediana Edad , Neoplasias/patología , Neoplasias Ováricas/patología , Plasmacitoma/diagnóstico , Rabdomiosarcoma/diagnósticoRESUMEN
One hundred consecutive outpatients seen in the colposcopy clinic of a private hospital had one or more Papanicolaou smears that suggested cervical atypia, dysplasia or carcinoma in situ. Of these 100 patients, 7% underwent a diagnostic cervical cone biopsy; 11% more had therapeutic conization. The accuracy of colposcopic examination with directed cervical biopsy within one level (under or over) of histologic findings was 88%; the cytologic accuracy within one level of histologic findings was 83%. The study showed that patients with cervical atypia at cytologic examination had dysplasia and carcinoma in situ at subsequent colposcopic cervical examination with directed biopsy.